R O Darouiche1, M D Mansouri. 1. Infectious Disease Section and Center for Prostheses Infection, Veterans Affairs Medical Center and Baylor College of Medicine, 1333 Moursund Avenue, Suite A221, Houston, TX 77030, USA. radarouiche@aol.com
Abstract
OBJECTIVES: Although active against free-floating bacteria, vancomycin displays a poor activity against organisms embedded within the biofilm surrounding implanted devices. Dalbavancin is a novel glycopeptide antibiotic with strong activity against staphylococci and a long half-life that allows for once-a-week dosing. The objective of this animal study was to examine the ability of dalbavancin and vancomycin to prevent Staphylococcus aureus colonization of devices. METHODS: Twelve rabbits were randomized, in three groups of four each, to receive intravenous injections of dalbavancin, vancomycin or normal saline (control). Eight polyurethane catheter segments were subcutaneously implanted in the back of each rabbit, then inoculated with S. aureus. Rabbits were sacrificed a week later and explanted devices were cultured. RESULTS: The rates of device colonization were comparable in the vancomycin (53%) and control (47%) groups, whereas only 28% of devices in the dalbavancin group became colonized. There was a trend (although not statistically significant) toward a lower rate of device colonization following receipt of dalbavancin vs. vancomycin (P = 0.07) or saline (P = 0.02). CONCLUSIONS: The demonstrated efficacy of dalbavancin in this animal study suggest that this novel antibiotic may have an important role in the prevention and treatment of device-related infection.
OBJECTIVES: Although active against free-floating bacteria, vancomycin displays a poor activity against organisms embedded within the biofilm surrounding implanted devices. Dalbavancin is a novel glycopeptide antibiotic with strong activity against staphylococci and a long half-life that allows for once-a-week dosing. The objective of this animal study was to examine the ability of dalbavancin and vancomycin to prevent Staphylococcus aureus colonization of devices. METHODS: Twelve rabbits were randomized, in three groups of four each, to receive intravenous injections of dalbavancin, vancomycin or normal saline (control). Eight polyurethane catheter segments were subcutaneously implanted in the back of each rabbit, then inoculated with S. aureus. Rabbits were sacrificed a week later and explanted devices were cultured. RESULTS: The rates of device colonization were comparable in the vancomycin (53%) and control (47%) groups, whereas only 28% of devices in the dalbavancin group became colonized. There was a trend (although not statistically significant) toward a lower rate of device colonization following receipt of dalbavancin vs. vancomycin (P = 0.07) or saline (P = 0.02). CONCLUSIONS: The demonstrated efficacy of dalbavancin in this animal study suggest that this novel antibiotic may have an important role in the prevention and treatment of device-related infection.
Authors: Dustin L Williams; Bryan S Haymond; Kassie L Woodbury; J Peter Beck; David E Moore; R Tyler Epperson; Roy D Bloebaum Journal: J Biomed Mater Res A Date: 2012-04-10 Impact factor: 4.396
Authors: Henry S Heine; Bret K Purcell; Jennifer Bassett; Lynda Miller; Beth P Goldstein Journal: Antimicrob Agents Chemother Date: 2010-01-04 Impact factor: 5.191
Authors: Dustin L Williams; Bryan S Haymond; James P Beck; Paul B Savage; Vinod Chaudhary; Richard T Epperson; Brooke Kawaguchi; Roy D Bloebaum Journal: Biomaterials Date: 2012-08-30 Impact factor: 12.479
Authors: Charles F Bellows; Benjamin M Wheatley; Krzysztof Moroz; Stephanie C Rosales; Lisa A Morici Journal: PLoS One Date: 2011-06-16 Impact factor: 3.240